PRODUCTS   METHODS
 
 
 

Human Autoimmune ELISA Kits

 
Product   Principle   Data   Literature   Price/Order   Message
 

 

 
 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.
 

Human Anti-dsDNA ELISA Kit EA-5002


Anti-dsDNA antibodies that appear to be critical in the pathogenesis of tissue injury are characteristic of systemic lupus erythematosus (SLE). There is a good correlation between anti-dsDNA antibody levels and disease activity. The overall detection rate of these antibodies is approximately 50-55% in SLE patients and about 89% in SLE patients with active renal disease. When they are present in high concentration, anti-dsDNA antibodies are virtually specific for SLE (>90%). Antibodies to dsDNA may disappear with immunosuppressive treatment and during remission. They rarely occur in other autoimmune disorders. Signosis has developed anti-dsDNA ELISA, a sandwich quantitative assay, to screen the presence of serum ds-DNA antibodies IgG.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-SSA (Ro-60) ELISA Kit EA-5003


Antibodies to the SSA antigen (also known as Ro antigen) are one of the most frequent serological markers of autoimmunity in rheumatic diseases. They appear in 60-70% of patients with Sjögren’s syndrome (SS), 30-40% of patients with systemic lupus erythematosus (SLE), and 3-5% of patients with rheumatoid arthritis (RA). The SSA antigen is comprised of an acidic 60 kDa protein that may exist in complex with RNA (80-112 bases). However, RNA is not required for SSA antigenicity. The SSA antigen is predominantly cytoplasmic, and not located in the nucleus. Therefore, patients with antibody to SSA may be ANA negative on routine testing. Approximately 62% of ANA negative lupus patients have antibodies to SSA. Two types of anti-Ro/SSA antibodies have been identified; Ro/SSA antigens of 60 kDa and 52 kDa. Anti-SSA-60 kDa antibodies are linked to certain disorders such as SS, SLE, neonatal lupus and congenital heart block. Clinically, the presence of aSSA52 has been reported in a wide variety of diseases, includes inflammatory myositis, primary biliary cirrhosis and SS.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-SSA (Ro-52) ELISA Kit EA-5004


Antibodies to the SSA antigen (also known as Ro antigen) are one of the most frequent serological markers of autoimmunity in rheumatic diseases. They appear in 60-70% of patients with Sjögren’s syndrome (SS), 30-40% of patients with systemic lupus erythematosus (SLE), and 3-5% of patients with rheumatoid arthritis (RA). The SSA antigen is comprised of an acidic 60 kDa protein that may exist in complex with RNA (80-112 bases). However, RNA is not required for SSA antigenicity. The SSA antigen is predominantly cytoplasmic, and not located in the nucleus. Therefore, patients with antibody to SSA may be ANA negative on routine testing. Approximately 62% of ANA negative lupus patients have antibodies to SSA. Two types of anti-Ro/SSA antibodies have been identified; Ro/SSA antigens of 60 kDa and 52 kDa. Anti-SSA-60 kDa antibodies are linked to certain disorders such as SS, SLE, neonatal lupus and congenital heart block. Clinically, the presence of aSSA52 has been reported in a wide variety of diseases, includes inflammatory myositis, primary biliary cirrhosis and SS.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-SSB (La) ELISA Kit EA-5005


The presence of antibodies against the SSB (also known as La) antigen has been advocated as a diagnostic marker for Sjogren's syndrome (SS), an autoimmune disease characterized by inflammation of the glands leading to diminished or absent glandular secretion. SS may present as a primary disease or associate with other systemic autoimmune diseases as secondary SS. The SSB antigen is a 47 kD ribonucleic protein associated with a spectrum of small RNAs and primarily resides in the nucleus. Antibodies to the SSB antigen appear in more than 80% of patients with primary or secondary SS. Anti-SSB antibodies usually co-present with anti-SSA antibodies, however due to more common of anti-SSA antibodies in other rheumatological conditions such as systemic lupus erythematosis (SLE) and mixed connective tissue disease (MCTD). It suggests that anti-SSB is more specific for primary and secondary SS than anti-SSA.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-U1-snRNP (68 kDa) ELISA Kit EA-5006


Mixed connective-tissue disease (MCTD) is an autoimmune disorder with coexistence and overlap of various connective-tissue diseases (CTDs) such as systemic lupus erythematosus (SLE); systemic sclerosis (SSc); dermatomyositis (DM); polymyositis (PM); and, occasionally, Sjögren syndrome. The presence of antibodies to specific components of U1-ribonucleoprotein (U1-RNP) complex is the immunological marker for the diagnosis of MCTD. The complex is composed of U-riched small nuclear RNA and a set of proteins, the 68 kDa (or 70 kDa) U1-specific protein plus proteins A and C and the Sm antigens (B, B`, D1, D2, D3, E, F, and G). Antibodies against the sn-RNP complex are directed against Sm as well as the 70 kDa U1-specific proteins plus proteins A and C. It is now known that the availability of RNP antigen in the absence of Sm is a good marker for MCTD.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-Scl-70 ELISA Kit EA-5007


Antibodies to Scl-70 are a specific immunological marker for scleroderma (or progressive systemic sclerosis, PSS), a systemic autoimmune disease characterized by collagen deposition and connective tissue destruction of the skin, blood vessels and certain internal organs. Studies have shown varying frequencies of Scl-70 antibodies in PSS. This antibody was found in approximately 20% of PSS patients in early studies but 75% in later studies. Scl-70 antibodies are directed against DNA-topoisomerase I which locates in the nucleus. The whole molecule of DNA-topoisomerase is 110 kDa but it is easily degraded by proteases to 100 kDa, 87 kDa and 70 kDa (Scl-70). PSS is classified into two types; diffuse scleroderma and limited scleroderma. Scl-70 antibodies are present specifically in diffuse scleroderma and centromere antibodies are present in limited scleroderma. Rarely, Scl-70 antibodies are found in SLE and MCTD patients.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-CENP-B ELISA Kit EA-5008


Anti-centromere antibodies (ACA) are an immunological marker for diagnosis of CREST syndrome, a limited form of systemic sclerosis. At least 9 proteins are known to be associated with the centromere complex, but CENP-B is normally considered to be the major centromere antigen. CENP-B has a molecular weight of approximately 66 kDa and plays an important role in the formation of the centromeric chromatin. CENP-B antibodies are present in the sera of up to 80% of patients with CREST syndrome. These autoantibodies are also often detected in sera from patients with Raynaud’s phenomenon and occasionally in other rheumatic diseases such as systemic lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis. ACA have also been reported to occur with high prevalence in patients with primary biliary cirrhosis, in patients with malignancies and occasionally in normal individuals.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-Jo-1 ELISA Kit EA-5009


Anti-Jo-1 antibody is a myositis specific autoantibody most commonly found in patients of Polymyositis (PM) and Dermatomyositis (DM). PM and DM are idiopathic inflammatory myopathies, characterized by proximal muscle weakness, elevated muscle enzyme activities and electromyographic and histological feature. This antibody is directed against the histidyl-tRNA synthetase which catalyses the binding of the histidine to its cognate tRNA during protein synthesis. Anti-Jo-1 antibody is predominantly found in 20-30% of PM patients and 60-70% of PM with interstitial pulmonary fibrosis. The antibody is also found in DM, although less frequently than in PM. , It is rare in children with PM or DM and in other connective tissue diseases. Moreover, the serum levels of anti-Jo-1 antibody strongly correlate with disease activity representing a good marker for disease monitoring.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-Histone ELISA Kit EA-5010


Anti-histone antibody is an important immunological marker for the diagnosis of drug induced lupus (DIL). Although anti-histone antibodies are detected in approximately 30% to 60% of patients with systemic lupus erythematosus (SLE), their presence is much higher in DIL patients. They are detected in about 95% of DIL patients, which is more important diagnostically. DIL is clinically similar to SLE, except that the former patients do not have kidney or central nervous system involvement. In addition, DIL patients do not demonstrate the multiple types of antinuclear antibodies (ANAs) often found in SLE patients.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Anti-SmD1 ELISA Kit EA-5011


Antibodies against the Sm antigens of the small nuclear ribonucleoproteins (snRNPs) are a very specific marker for the diagnosis of systemic lupus erythematosus (SLE). Antibodies against the Sm proteins are found in 20-30% of SLE patients. Anti-Sm antibodies are observed at a high titer in the active period of SLE and at a low titer in the non-active period. Antibodies directed against Sm proteins as well as DNA found in sera from patients with SLE have been included as one of the American College of Rheumatology classification criteria for SLE. Sm antigen is now known to be consisted of at least nine different polypeptides. Anti-Sm antibodies are predominantly directed against the SmD1 protein of the snRNP complex.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human ANA ELISA Kit EA-5013


Anti-nuclear antibodies (ANA) are a group of antibodies directed against various nuclear and some cytoplasmic antigens. Although these antibodies were first associated with systemic lupus erythematosus (SLE), the list of implicated diseases has expanded and many rheumatic diseases are characterized by the presence of one or more of these ANAs. For instance, anti-SSA/Ro and anti-SSB/La antibodies are associated with SLE and Sjogren's Syndrome (SS), anti-dsDNA and anti-Sm antibodies with SLE, anti-histone antibodies with SLE and Drug Induced Lupus, anti-RNP antibodies with mixed connective tissue disease (MCTD) and SLE, anti-Scl-70 antibodies with scleroderma (progressive systemic sclerosis (PSSJ), anti-Jo1 with polymyositis and dermatomyositis and anti-centromere antibodies with CREST syndrome. ANA are usually detected by indirect immunofluorescence (IFA) on HEp-2. Because of certain limitations of IFA, ANA ELISA test is more robust offering several advantages including ease of operation and not requiring skills needed to perform and read IFA reactions. ANA ELISA test is able to efficiently screen large numbers of patient samples and reduces human error. As ANA ELISA test collectively detects, in one well, total ANAs against double stranded DNA (dsDNA), Histones, SS-A/Ro, SS-B/La, Sm, Sm/RNP, Scl-70, Jo-1, and centromeric antigens, more specific antibody tests are recommended to perform in patients with positive ANA.

 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.



Human Eight-ANA ELISA Screen Assay EA-5101


Anti-nuclear antibodies (ANA) are a group of antibodies directed against various nuclear and some cytoplasmic antigens. Serological tests for ANA play an important role towards the diagnosis of various autoimmune connective tissue disorders. Although these antibodies were first associated with systemic lupus erythematosus (SLE), the list of implicated diseases has expanded and many rheumatic diseases are characterized by the presence of one or more of these ANAs. For instance, anti-SSA/Ro and anti-SSB/La antibodies are associated with SLE and Sjogren's Syndrome (SS), anti-dsDNA and anti-Sm antibodies with SLE, anti-RNP antibodies with mixed connective tissue disease (MCTD) and SLE, anti-Scl-70 antibodies with scleroderma (progressive systemic sclerosis (PSSJ), anti-Jo1 with polymyositis and dermatomyositis and anti-centromere antibodies with CREST syndrome. As ANA ELISA test collectively detects, in one well, total ANAs against double stranded DNA (dsDNA), Sm, U1-RNP (68K), SS-A/Ro, SS-B/La, Scl-70, Jo-1, and centromeric antigens, along with sera positive for IFA HEp-2 ANAs, it is not specific indicators of a connective tissue disease. To monitor more specific antibodies, eight different antigens (dsDNA, SmD1, U1-RNA (68K), SS-A/Ro, SS-B/La, Scl-70, Jo-1, and CENP-B) are coated to different wells in a column or strip for the ELISA screen test of eight different autoimmune antibodies once.

 

List of Applicable ANAs

dsDNA SmD1 U1-RNA SS-A/Ro SS-B/La Scl-70 Jo-1 CENP-B
 
Benefits:
  • Cost-effective analysis - High quality with an affordable price.
  • Efficient and flexible - Multiple samples can be analyzed simultaneously with a flexible number of assay wells.

  • Simple procedure - All in one system with a pre-coated 96-well plate.